Page last updated: 2024-09-03

rti 121 and oxidopamine

rti 121 has been researched along with oxidopamine in 5 studies

Compound Research Comparison

Studies
(rti 121)
Trials
(rti 121)
Recent Studies (post-2010)
(rti 121)
Studies
(oxidopamine)
Trials
(oxidopamine)
Recent Studies (post-2010) (oxidopamine)
641118,63062,407

Protein Interaction Comparison

ProteinTaxonomyrti 121 (IC50)oxidopamine (IC50)
Glyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)8
DNA repair protein RAD52 homologHomo sapiens (human)0.779

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bohn, MC; Connor, B; Elsworth, JD; Kozlowski, DA; Schallert, T; Tillerson, JL; Unnerstall, JR1
Bordia, T; Huang, LZ; Michael McIntosh, J; Parameswaran, N; Quik, M1
Crossman, AR; Kobylecki, C; Ravenscroft, P1
Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M1
Bordia, T; Perez, XA; Quik, M; Zhang, D1

Other Studies

5 other study(ies) available for rti 121 and oxidopamine

ArticleYear
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Experimental neurology, 2001, Volume: 169, Issue:1

    Topics: Aging; Animals; Autoradiography; Carrier Proteins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Male; Membrane Glycoproteins; Membrane Transport Proteins; Microinjections; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Presynaptic Terminals; Rats; Rats, Inbred F344; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase

2001
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
    Journal of neurochemistry, 2009, Volume: 109, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Analysis of Variance; Animals; Autoradiography; Cocaine; Conotoxins; Corpus Striatum; Cotinine; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Iodine Isotopes; Male; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Nicotine; Oxidopamine; Protein Binding; Rats; Rats, Sprague-Dawley; Saimiri; Substantia Nigra; Time Factors

2009
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Experimental neurology, 2013, Volume: 247

    Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics

2013
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
    Neuroscience, 2015, Jun-04, Volume: 295

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic

2015
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:4

    Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics

2017